ArticleFrontiers in genetics2025
Cancer classification in high dimensional microarray gene expressions by feature selection using eagle prey optimization.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal feature-optimized approaches for cancer classification using microarray gene expression analysis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microarray gene expression data have emerged as powerful tools in cancer classification and diagnosis. However, the high dimensionality of these datasets presents significant challenges for feature selection, leading to the development of various computational methods. In this paper, we utilized the Eagle Prey Optimization (EPO), a novel genetically inspired approach for microarray gene selection in cancer classification. EPO draws inspiration from the remarkable hunting strategies of eagles, which exhibit unparalleled precision and efficiency in capturing prey. Similarly, our algorithm aims to identify a small subset of informative genes that can discriminate between cancer subtypes with high accuracy and minimal redundancy. To achieve this, EPO employs a combination of genetic mutation operator with EPO fitness function, to evolve a population of potential gene subsets over multiple generations. The key innovation of EPO lies in its incorporation of a fitness function specifically designed for cancer classification tasks. This function considers not only the discriminative power of selected genes but also their diversity and redundancy, ensuring the creation of compact and informative gene subsets. Moreover, EPO incorporates a mechanism for adaptive mutation rates, allowing the algorithm to explore the search space efficiently. To validate the effectiveness of EPO, extensive experiments were conducted on several publicly available microarray datasets representing different cancer types. Comparative analysis with state-of-the-art gene selection algorithms demonstrates that EPO consistently outperforms these methods in terms of classification accuracy, dimensionality reduction, and robustness to noise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.